EGFR
Epidermal growth factor receptor; ErbB-1; HER1
The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.
EGFR Isoform Specific Products
All Product Categories
-
EGFR Inhibitors
(1035)
View all products
-
EGFR Agonists
(4)
View all products
-
EGFR Antagonists
(5)
View all products
-
EGFR Activators
(8)
View all products
-
EGFR Modulators
(7)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(4)
View all products
-
EGFR Degraders
(45)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(19)
View all products
-
ErbB2/HER2 Proteins
(39)
View all products
-
ErbB3/HER3 Proteins
(15)
View all products
-
EGFR Proteins
(46)
View all products
-
ErbB4/HER4 Proteins
(10)
View all products
-
EGFR Related Products (1259)
Related Products (1259)
-
Recombinant Proteins (110)
-
Antibodies (19)
-
EGFR Isoform Comparison
-
EGFR-IN-160
0 ImagesCat. No.: HY-173619CAS No.: 2172879-84-2EGFR-IN-160 (Compound R12) is an EGFR inhibitor (IC50 values are 1.62, 0.49 and 0.98 μM for EGFRWT, EGFRT790M and EGFRL858R/T790M/C797S, respectively). EGFR-IN-160 induces G2/M and S phase arrest and apoptosis in NCI-H522 cells, and has anticancer activity. EGFR-IN-160 has antioxidant effects against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).
-
EGFR-IN-209
0 ImagesCat. No.: HY-183277CAS No.: 3088042-00-3EGFR-IN-209 (Compound 6g) is an orally active, selective EGFRDel19/T790M/C797S inhibitor with an IC50 of 0.056 μM. EGFR-IN-209 blocks the phosphorylation of EGFR and its downstream effector molecules (pMAPK, pAKT). EGFR-IN-209 induces Apoptosis. EGFR-IN-209 exhibits antitumor activity against Osimertinib (HY-15772)-resistant non-small cell lung cancer. EGFR-IN-209 can be used in research related to non-small cell lung cancer.
-
VEGFR-2-IN-88
0 ImagesCat. No.: HY-184719VEGFR-2-IN-88 is a VEGFR-2 inhibitor with an IC50 of 0.202 μM. VEGFR-2-IN-88 potently inhibits EGFR (IC50 = 0.139 μM), and moderately inhibits PDGFR-β (IC50 of 0.236 μM) and c-Met (IC50 of 0.281 μM). VEGFR-2-IN-88 acts as a cell cycle inhibitor that arrests cells at the G0/G1 phase. VEGFR-2-IN-88 induces Apoptosis. VEGFR-2-IN-88 downregulates serum AST and ALT levels. VEGFR-2-IN-88 exerts selective anticancer effects. VEGFR-2-IN-88 reduces liver weight in in vivo models. VEGFR-2-IN-88 can be used in research related to hepatocellular carcinoma.
-
MM-151
0 ImagesCat. No.: HY-P991572CAS No.: 1399724-72-1MM-151 is a humanized IgG1 monoclonal antibody targeting EGFR. MM-151 binds multiple regions of the EGFR extracellular domain (ECD) and reduces its mutations in circulating cell-free tumor DNA with EGFR resistance. MM-151 significantly inhibits EGFR signaling and cell growth. MM-151 can be used for drug-resistant cancers research, such as colorectal, non-small cell lung and triple negative breast cancer.
-
PD 173955 analog 1
0 ImagesCat. No.: HY-18298CAS No.: 185039-99-0
-
EGFR/HER2/DHFR-IN-3
0 ImagesCat. No.: HY-149633EGFR/HER2/DHFR-IN-3 (compound 4c) is a potent dual inhibitor of EGFR/HER2, with IC50s of 0.138 and 0.092 μM, respectively. EGFR/HER2/DHFR-IN-3 also inhibits DHFR, with an IC50 of 0.193 M. EGFR/HER2/DHFR-IN-3 causes arrest at the S phase of the cell cycle and induces apoptosis in MCF7 breast cancer cells.
-
EGFR-IN-166
0 ImagesCat. No.: HY-175173CAS No.: 503443-98-9EGFR-IN-166 (Compound 2) is a EGFR inhibitor. EGFR-IN-166 has potent anticancer activity against breast cancer cells with IC50s of 69.63 and 22.84 μM for MCF-7 and MDA-MB-231 cells, respectively. EGFR-IN-166 significantly inhibits cell migration and EGFR expression. EGFR-IN-166 can be used for breast cancer research.
-
EGFR-IN-57
0 ImagesCat. No.: HY-146138CAS No.: 2492382-37-1EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis.
-
EGFR-PK/JNK-2-IN-1
0 ImagesCat. No.: HY-162332CAS No.: 3034838-06-4
-
Erbb2 Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS04467Erbb2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
EGFR/microtubule-IN-1
0 ImagesCat. No.: HY-161145CAS No.: 1970269-96-5
-
Anti-Her4 Antibody
0 ImagesCat. No.: HY-P991985
-
EGFR-IN-16
0 ImagesCat. No.: HY-137786CAS No.: 133550-22-8
-
G7-18NATE
0 ImagesCat. No.: HY-P10224CAS No.: 936728-13-1G7-18NATE is a peptide inhibitor of Grb7. HY-P10224 binds to the Grb7-SH2 domain with micromolar affinity (KD = 18.1 μM). G7-18NATE inhibits cell proliferation, motility, cell invasion and 3D culture formation in several cancer cell lines.
-
COX/5-LO-IN-2
0 ImagesCat. No.: HY-181061COX/5-LO-IN-2 is a COX2, EGFR, COX1, 5-LOX, BRAF and FAK inhibitor with IC50 of 1.22 μM, 2.5 μM, 2.95 μM, 4.65 μM, 7.4 μM, 12.2 μM, respectively. COX/5-LO-IN-2 induces cell growth arrest at G2/M phase. COX/5-LO-IN-2 triggers apoptotic activity by up-regulating proapoptotic proteins p53, Bax, and caspase-7 and down-regulating anti-apoptotic protein Bcl-2. COX/5-LO-IN-2 can be used for the research of breast cancer.
-
EGFR-IN-109
0 ImagesCat. No.: HY-162360CAS No.: 3019971-97-9
-
Afatinib-d6 dimaleate
0 ImagesCat. No.: HY-10261ASSynonyms: BIBW 2992MA2-d6Afatinib-d6 (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
